RAI1 Gene: Potential Drug Target, Biomarker for Various Diseases

Target Name: RAI1

NCBI ID: G10743

RAI1

RAI1 Gene: Potential Drug Target, Biomarker for Various Diseases

RAI1 (Smith-Magenis syndrome chromosome region) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative disorders, and psychiatric conditions. The RAI1 gene is located on chromosome 17 and is responsible for the production of a protein known as RAB17, which plays a critical role in regulating cell growth and division.

The discovery of the RAI1 gene and its associated proteins began in the late 1980s, when researchers identified a region of the chromosome that was highly recurrently deleted in individuals with Smith-Magenis syndrome, a rare genetic disorder that affects the development of skeletal muscles. The deleted region included the RAI1 gene, which encodes the RAB17 protein.

Since then, numerous studies have demonstrated that individuals with Smith-Magenis syndrome have reduced levels of RAB17 and that inhibiting the activity of RAB17 may be a promising strategy for the treatment of this disorder. Researchers have also found that individuals with neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, also have reduced levels of RAB17 and that targeting this protein may be a potential treatment for these conditions.

In addition to its potential as a drug target, the RAI1 gene has also been identified as a potential biomarker for various diseases. The RAB17 protein is highly expressed in many tissues and cells, including cancer cells, and has been shown to play a role in the development and progression of cancer. Therefore, the RAI1 gene may be a useful biomarker for the detection and monitoring of cancer.

Furthermore, the RAI1 gene has also been associated with several psychiatric conditions, including depression and anxiety. Studies have shown that individuals with Smith-Magenis syndrome are more likely to experience symptoms of depression and anxiety than those without the disorder. Additionally, individuals with neurodegenerative disorders, such as Alzheimer's disease, have been shown to have increased levels of RAB17 and to have reduced levels of the RAB17 protein in their brain.

In conclusion, the RAI1 gene is a promising drug target and biomarker for the treatment of various diseases, including cancer, neurodegenerative disorders, and psychiatric conditions. The discovery of this gene and its associated proteins has opened up new avenues of research and has the potential to lead to the development of new treatments for a variety of conditions. Further research is needed to fully understand the role of the RAI1 gene and its potential as a drug target and biomarker.

Protein Name: Retinoic Acid Induced 1

Functions: Transcriptional regulator of the circadian clock components: CLOCK, BMAL1, BMAL2, PER1/3, CRY1/2, NR1D1/2 and RORA/C. Positively regulates the transcriptional activity of CLOCK a core component of the circadian clock. Regulates transcription through chromatin remodeling by interacting with other proteins in chromatin as well as proteins in the basic transcriptional machinery. May be important for embryonic and postnatal development. May be involved in neuronal differentiation

The "RAI1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAI1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets